A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer

The main objectives of this study are to determine the feasibility and safety of Belzupacap Sarotalocan (AU-011, bel-sar) treatment of bladder cancer utilizing focal injections with or without laser application.

Trial Details

NCT ID
NCT05483868
Phase
PHASE1
Sponsor
Aura Biosciences
Status
RECRUITING
Cancer Type
Non-Muscle-Invasive Bladder Cancer
Interventions
  • AU-011
  • AU-011 in Combination with Medical Laser Adminstration
  • AU-011 in Combination with Medical Laser Administration
Locations (sample)
  • Little Rock, Arkansas, United States|34.74648,-92.28959
  • Los Angeles, California, United States|34.05223,-118.24368
  • Santa Monica, California, United States|34.01949,-118.49138
  • The Bronx, New York, United States|40.84985,-73.86641
  • Myrtle Beach, South Carolina, United States|33.68906,-78.88669

Key Eligibility Criteria

  • Meet the following histopathologic requirements for urothelial carcinoma:
  • For Cohorts 1b, 4a-c:
  • histopathological diagnosis of NMIBC (any grade) is required. For participants with first diagnosis of NMIBC, confirmation of urothelial carcinoma …
  • For Cohorts 4d, 4e, 4g and 4h, a diagnosis of LG IR NMIBC (according to

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Muscle-Invasive Bladder Cancer Trials on Trialify →